1.Multi-center Survey on Off-label Drug Use of Ambroxol Hydrochloride Injection
Yingtong ZENG ; Lu LIN ; Sha LAI ; Yuguan WEN ; Wenjing QIAN ; Luanluan CHEN ; Dayi JIANG ; Qingqun CAI ; Xiang GAO
China Pharmacy 2017;28(29):4060-4065
OBJECTIVE:To investigate off-label drug use of Ambroxol hydrochloride injection,and to provide reference for further evidence-based evaluation on rationality and standardized management of off-label drug use. METHODS:All medical orders for inpatients receiving Ambroxol hydrochloride injection were selected from 10 hospitals of Guangdong province during Apr. 2014 to Mar. 2015. Situation of drug use in different categories of departments was summarized,the incidence of off-label administation route and off-label dosage were analyzed;according to drug package inserts,prescription daily dose(PDD)and drug utilization in-dex(DUI)were calculated for each category of department,and the degree of off-label dosage was evaluated. RESULTS:A total of 761 821 person·day who used Ambroxol hydrochloride injection was included. Off-label drug use occurred in each category of departments,and the incidence of off-label drug use was 62.10%. The incidence of off-label administration route was 40.51%, mainly atomization inhalation;the incidence of it was the high-est in gynecology and obstetrics department(92.70%).The in-cidence of off-label dosage was 36.30%,and the incidence of it was the highest in cardiothoracic surgery department (85.36%). Departments whose PDDs were higher than the drug package inserts were cardiothoracic surgery department,ICU,surgical department,cardiovascular medicine department,emer-gency department,department of internal medicine and pediatrics department.CONCLUSIONS:Off-label drug use of Ambroxol hy-drochloride injection is common,and the effectiveness,safety and necessity remain controversial,which need to be proved by multi-center randomized controlled prospective trial.
2.Periodic revalidation of autoverification for blood analysis and its suitability evaluation of application
Yingtong LI ; Xuejun WANG ; Wei XU ; Linlin QU ; Xianqiu CHEN ; Lijing WEI ; Ying WANG ; Hongli SHAN ; Zongxing YANG ; Yue CAI ; Xiaoquan YANG ; Wenrui SUN ; Dan LI ; Yue ZHANG ; Xi WANG ; Jin LIANG ; Jing HUANG ; Jiancheng XU ; Haiyan WANG ; Fang LIU ; Weining JIANG ; Chengming SHANG
Chinese Journal of Laboratory Medicine 2020;43(10):1021-1031
Objective:To conduct periodic revalidation of the 15 items and 43 terms autoverification rules of blood analysis after 1 year of application, analyze the application suitability and make the rules improved.Methods:Track the results of 528 010 blood analysis samples of our hospital from August 1, 2019 to January 31, 2020, and analyze the pass rate and interception rate of autoverification; 600 specimens in total were selected randomly for microscope examination, including 300 specimens which touched autoverification rules (1 012 items of autoverification rules) and were intercepted by autoverification and 300 specimens which untouched autoverification rules and were released by autoverification. The abnormal characteristics and unacceptable Delta check of the specimens also need to be concerned at the same time.The false negative rate and false positive rate, true negative rate, true positive rate and pass correct rate of autoverification were verified and compared with the rate of the second phase verification when the autoverification rule was established. The false negative rate, false positive rate, true negative rate and true positive rate of the Delta check rule which 54 716 specimens touched were calculated and compared with the second phase verification rate when the autoverification rule was established.The results of microscopic examination were used as the gold standard for the calculation of the rates, and P<0.05 was considered as a significant difference. The false positive and true positive of 1 012 autoverification rules were analyzed item by item.The false positive and true positive of 108 specimens which touched blast cell autoverification rule were analyzed terms by terms. The mean TAT and median TAT of 528 010 specimens and 193 750 outpatient specimens were calculated respectively, and the report percentages of 528 010 samples that TAT<30, 30-60 and>60 min were calculated respectively. Analyze and evaluate the application suitability of autoverification rules to juge whether they meet the needs of doctors and laboratory. The design process and the rules and application process of autoverification were optimized and improved.Results:The autoverification pass rate was 63.06% (332 971/528 010), the interception rate was 36.94% (195 039/528 010). The false negative rate was 1.00% (1/600), the false positive rate was 12.67% (76/600), the true negative rate was 49% (294/600), the true positive rate was 37.33% (224/600), and the correct rate was 98% (294/300). The pass rate, true negative rate, true positive rate and correct rate of the periodic reverification group were higher than the second phase verification group, the false negative rate and false positive rate were lower than that the second phase verification group. The false negative rate and true positive rate of the Delta check of periodic verification group were lower than that the second phase verification group, the false positive rate and true negative rate were higher than the second phase verification group, there were significant differences in the comparition results. The mean TAT of 528 010 specimens was25 min, and the median TAT was 22 min. The mean TAT of 193 750 outpatient specimens was 23 min, and the median TAT was 20 min. The report percentages of 528 010 samples that TAT<30 min, 30 min-60 min and>60 min were 83.30% (439 819/528 010), 8.00% (42 250/528 010) and 8.70% (45 941/528 010), respectively.Conclusion:The results of periodic revalidation of autoverification after 1 years application show that the 15 items and 43 terms autoverification rules of blood analysis could meet requirements about the accuracy and efficiency of the laboratory, and have a good suitability for application.
3.The effect of Er: YAG laser irradiation on bonding properties of IPS e.max CAD ceramics
HOU Yepo ; SHEN Renze ; CHEN Luyuan ; CHEN Yi ; JIANG Yingtong ; LI Jingmei ; GAO Jie
Journal of Prevention and Treatment for Stomatological Diseases 2018;26(2):95-98
Objective:
To investigate different Er:YAG laser power settings on the bonding properties of IPS e.max CAD ceramics.
Methods :
96 IPS e.max CAD ceramics blocks (5 mm × 5 mm × 5 mm) were prepared and randomly divided into 8 groups (n = 12), the untreated blocks served as the control, while one of the experimental groups was treated with 4.5% HF for 20 seconds, six remaining test group (C、D、E、F、G、H) were treated with different Er: YAG laser power settings: 100 mJ、200 mJ、300 mJ、400 mJ、500 mJ and 600 mJ. Morphology of the ceramic surface was observed by atomic force microscopy and its shear bond strength (SBS) was tested.
Results :
Higher shear bond strength values were found in group C-H compared to group B, the highest is group F (24.12 ± 1.91) MPa. The difference was statistically significant. The atomic force microscope observation of the surface structure showed that the control group was smooth and flat, and the HF-like etching group formed a uniform needle-like convex structure. The laser group gradually formed a regularly arranged cylindrical convex structure, in which the surface of the G and H groups was damaged.
Conclusion
The Er: YAG laser power settings of 400 mJ can be used as an effective pretreatment method before bonding of IPS e.max CAD ceramic.
4.Research progress on the role and mechanism of miR-155 in the development of oral squamous cell carcinoma
HUANG Lihuan ; JIANG Yingtong ; OUYANG Kexiong ; WU Lihong ; YANG Xuechao
Journal of Prevention and Treatment for Stomatological Diseases 2019;27(12):809-812
Oral squamous cell carcinoma (OSCC) is the most common oral cancer. Previous studies have found significantly high miR-155 expression in OSCC. However, the mechanism by which miR-155 plays a role in OSCC oncogenesis is not yet clear. This article reviews the function of the relationship between miR-155 and tumors and the potential role of miR-155 in the development of OSCC. A literature review showed that mir-155, as a small carcinogenic RNA, can inhibit CDC73, BCL6, P27Kip1 and other target genes that play a role in cancer inhibition; promote the proliferation, migration and invasion of OSCC cells; and inhibit apoptosis. miR-155 can also be combined with biological factors (Epstein-Barr virus, human papillomavirus) to promote the development of OSCC.